Market Access Program

TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
火曜日, 11月 14, 2023
Corporation, Research, Exercise, EAP, Clinical trial, Mortality, Microsoft Access, Administration, Insurance, Patient, Research and development, Calendar, G&A, Hook effect, BioRxiv, R, TFF, Medication, Market Access Program, Pharmaceutical industry, Cryptocurrency

FORT WORTH, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the third quarter of 2023 and provided a corporate update.

Key Points: 
  • FORT WORTH, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the third quarter of 2023 and provided a corporate update.
  • For the quarter ended September 30, 2023, compared to quarter ended September 30, 2022
    Cash Position: as of September 30, 2023, TFF Pharmaceuticals reported cash and cash equivalents of $9.7 million.
  • Net Loss: TFF Pharmaceuticals reported a net loss for the third quarter of 2023 of $4.4 million, compared to a net loss of $7.3 million for the comparable period in 2022.
  • The Company will host a conference call today, Tuesday, November 14, 2023, at 4:30 PM Eastern Time, to discuss third quarter 2023 financial results and the corporate update.

ZwitterCo Announces Manufacturing and Engineering Executive Jennifer Rehder as New Vice President of Operations

Retrieved on: 
木曜日, 11月 9, 2023
Water, Food, Market Access Program, Engineering, DuPont, Rehder, Agriculture, Sewage treatment, Renewable energy

BOSTON, Nov. 9, 2023 /PRNewswire/ -- ZwitterCo, the advanced membrane technology company, today announced the appointment of industry veteran Jennifer Rehder as the company's new vice president of operations. With its breakthrough zwitterionic membrane technology, ZwitterCo enables industries to reuse their previously unrecoverable wastewater. The company's membranes offer a cost-effective and reliable path for industries to achieve water security, building resilience in global manufacturing, food, and energy systems.

Key Points: 
  • BOSTON, Nov. 9, 2023 /PRNewswire/ -- ZwitterCo , the advanced membrane technology company, today announced the appointment of industry veteran Jennifer Rehder as the company's new vice president of operations.
  • The company's membranes offer a cost-effective and reliable path for industries to achieve water security, building resilience in global manufacturing, food, and energy systems.
  • As an expert in developing and leading world-class membrane manufacturing centers, Rehder will drive the expansion of ZwitterCo's operations function and support the company's global commercial growth.
  • Most recently, Rehder was vice president of manufacturing and engineering at Harvey Vogel Manufacturing Co., where she led the planning and execution of manufacturing and engineering objectives.

Citizens Against Government Waste Releases $4 Trillion in Prime Waste-Cutting Recommendations

Retrieved on: 
木曜日, 10月 5, 2023
Technology, Labor, Homeland Security, Courts, Elections, Campaigns, Law Enforcement, Emergency Services, Congressional News, Views, Healthcare Reform, Public Policy, Government, Advocacy Group Opinion, Internet, White House, Federal Government, Other Policy Issues, Congress, Market Access Program, Government Accountability Office, CAGW, Fraud, Congressional Budget Office, MAP, Citizens Against Government Waste, Medicare, Federation, Reading, Fossil fuel, Pharmaceutical industry

Today, Citizens Against Government Waste (CAGW) released Prime Cuts 2023 , the latest edition of the group’s comprehensive recommendations to eliminate waste, fraud, abuse, and mismanagement in the federal government.

Key Points: 
  • Today, Citizens Against Government Waste (CAGW) released Prime Cuts 2023 , the latest edition of the group’s comprehensive recommendations to eliminate waste, fraud, abuse, and mismanagement in the federal government.
  • Total savings from Prime Cuts 2023 are $402.3 billion in the first year and $4 trillion over five years.
  • There are 543 recommendations from bipartisan and nonpartisan sources, including the Government Accountability Office, Congressional Budget Office, and the budgets of former Presidents Trump and Obama.
  • Since CAGW’s inception in 1984, implementation of the group’s recommendations has helped save taxpayers more than $2.4 trillion.

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
木曜日, 7月 13, 2023
State University of New York, AACR, EAP, GCC, Half-life, HPHA, ATAC, SRC, Binghamton University, Multiple myeloma, Clinical trial, State university system, Bone marrow, Cancer, American Association for Cancer Research, FSE, Magenta, Research, ATACS, Sale, Spanish mythology, Amanitin, Data analysis, CAIX, Patient, Antibody-drug conjugate, Microsoft Access, Marketing, CFO, Management, Ethics, ADC, Eli Lilly and Company, Depreciation, Spacecraft, Phase, FDA, Therapy, Market Access Program, Safety, Disease, Pharmaceutical industry, Vaccine, Fine chemical, Generic drug, Cryptocurrency, Telix, Emergence

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

EQS-News: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients

Retrieved on: 
木曜日, 7月 6, 2023
MSD, HSV, Letermovir, Aciclovir, EAP, Therapy, Cytomegalovirus, Diabetes, Infection, ADV, Eye, Cancer, Breakthrough therapy, Research, DSM-IV codes, RNA, Life expectancy, HSCT, US, EKC, Radiation, AIDS, Patient, System Infected: Backdoor VBS Dunihi, CMV, Nightfall and Other Stories, CFO, Pritelivir, Merck, BKV, Merck & Co., Immunodeficiency, BK virus, Market Access Program, BK, Vaccine, Fine chemical, Pharmaceutical industry

AiCuris to continue its transition into a fully integrated biopharmaceutical company leveraging its research, clinical development, and commercialization expertise.

Key Points: 
  • AiCuris to continue its transition into a fully integrated biopharmaceutical company leveraging its research, clinical development, and commercialization expertise.
  • With AiCuris’ enhanced focus on development and commercialization of anti-infectives for immunocompromised individuals, the Company will discontinue research activities outside of this strategic scope.
  • Larry Edwards, CEO of AiCuris Anti-infective Cures AG, said: “Immunocompromised patients develop severe, partially life-threatening disease from infections that are typically well controlled in immune competent individuals.
  • Highly prevalent latent virus infections such as CMV, HSV and BKV can cause severe complications in immunocompromised patients for example, after transplantations.

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

Retrieved on: 
水曜日, 3月 22, 2023
PD, Marketing, Biogen, Head, G&A, MBA, Science, Patient, Investment, Microsoft Access, Shire (pharmaceutical company), Infant, R, Research and development, EAP, Therapy, Research, Kidney disease, Consultant, UCB, Shire, TKT, FDA, IND, Safety, Myasthenia gravis, Multiple sclerosis, Administration, PXE, Master of Science, Calciphylaxis, Market Access Program, PK, CRISPR, Clinical trial, Channel, ESKD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Dietary supplement, Management, Nursing, Cryptocurrency

BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2022, and provided recent business highlights. The Company also today announced that founding chief executive officer (CEO), Axel Bolte, MSc, MBA, will retire from his current role and that Douglas A. Treco, Ph.D., chairman of the Company’s board of directors (Board), will succeed Mr. Bolte as the CEO of the Company, effective April 1, 2023.

Key Points: 
  • BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2022, and provided recent business highlights.
  • I look forward to continuing to benefit from his experience as a senior advisor and Board member,” said Dr. Treco.
  • Axel Bolte, MSc, MBA, the Company’s founding CEO will retire and continue to work with Inozyme as a senior advisor and serve on the Board.
  • Dr. Winton most recently served as senior vice president and head of the Multiple Sclerosis franchise for Biogen’s US organization.

Applitools Centra Connects Design and Development to Deliver Better Customer Experiences

Retrieved on: 
火曜日, 3月 7, 2023
History, Artifact, SAN, Communication, Market Access Program, UX, QA, Documentation, Quality assurance, Marketing, Automation, Online shopping, Design, Industrial design, Centra, UI

SAN MATEO, Calif., March 7, 2023 /PRNewswire/ -- Applitools, provider of the next generation test automation platform powered by Visual AI, today announced the launch of an Early Access Program for Centra, a new tool designed to connect teams across the product delivery lifecycle.  Centra will be free to use for teams and anyone visiting Applitools.com will be able to sign up immediately for the waitlist.

Key Points: 
  • You can sign up for the waitlist for Applitools Centra using this link: https://applitools.com/centra
    As the modern application UX continues to evolve, the design to development handoff process continues to challenge even the best frontend teams.
  • "Applitools Centra helps teams ensure the exact experience that was meant for users is what makes it to production.
  • According to a Gartner® report, "To deliver an engaging UX for customers and employees, software engineering leaders must overcome the divide between development and design.
  • To do this, you need people with inspiration and the communication skills to bridge the gaps between development and design.

SIFI ANNOUNCES LICENSE AGREEMENT WITH AVANZANITE BIOSCIENCE FOR AKANTIOR®

Retrieved on: 
火曜日, 1月 10, 2023
Partnership, Food, European Medicines Agency, Country, Acanthamoeba keratitis, Ophthalmology, European Directive on Traditional Herbal Medicinal Products, EAP, Patient, American Academy, Committee, US Foods, Market Access Program, Investment, FDA, MAA, European Economic Area, EMA, Pharmaceutical industry, Renewable energy

SIFI will focus its European market access and commercial activities on existing markets, and the new markets Germany and the United Kingdom.

Key Points: 
  • SIFI will focus its European market access and commercial activities on existing markets, and the new markets Germany and the United Kingdom.
  • CATANIA, Italy, Jan. 10, 2023 /PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered in Italy, today announced that it has partnered with Avanzanite Bioscience (Avanzanite), a Dutch specialty pharmaceutical company, to exclusively commercialize and distribute AKANTIOR® (polihexanide) in 26 Countries within the European Economic Area and Switzerland.
  • Under the terms of the agreement, SIFI will handle all ongoing regulatory activities, whilst Avanzanite will focus on market access, distribution and commercial activities in those markets.
  • SIFI and Avanzanite also agreed to expand the Early Access Program (EAP) already in place for the big 5 European Countries to selected Countries within the scope of the license to Avanzanite.

KemPharm Announces Appointment of Christopher Posner as New Independent Director

Retrieved on: 
火曜日, 11月 29, 2022
Marketing, KMPH, Regulation of tobacco by the U.S. Food and Drug Administration, NPC, EAP, Security (finance), Neurodegeneration, Organization, Economics, LEO, Pfizer, Policy, Patient, Market Access Program, Hydrocodone, NDA, Investigational New Drug, Paracetamol, Fuqua School, Niemann–Pick disease, New Drug Application, FDA, SDX, Food, Narcolepsy, Idiopathic hypersomnia, Glycogen storage disease, Duke University, Clinical trial, ADHD, Triple accreditation, Bristol Myers Squibb, Benzhydrocodone, Villanova University, Central nervous system, CNS, Leo Pharma, Endo International, IH, Business, Pharmaceutical industry

CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.

Key Points: 
  • Mr. Posner is currently the president and CEO of Cara Therapeutics (Nasdaq: CARA), a commercial-stage biopharmaceutical company.
  • He brings more than 20 years of global pharmaceutical experience to KemPharm, including expertise in preparing and executing commercial product launches.
  • Prior to joining Cara Therapeutics, Mr. Posner was President and Chief Executive Officer of LEO Pharma, Inc., the U.S. subsidiary of LEO Pharma A/S.
  • I welcome the opportunity to join KemPharm at a very exciting period for the company, said Mr. Posner.

MessageMedia Announces Integration Into BigCommerce Platform to Streamline Two-Way Customer Engagement for Retailers

Retrieved on: 
木曜日, 11月 3, 2022
HubSpot, ROI, Education, EAP, Industry, Solution, Love, Public, Software as a service, SMS, CO, NetSuite, Automation, Nasdaq, Marketing, Health, Organization, BigCommerce, CRM, Skullcandy, NASDAQ, Partnership, ERP, B2C, Market Access Program, Human, Technology, B2B, BIGC, Efficiency, Online shopping, Mobile phone, Weapon, Vodafone, Facebook, Sinch

Businesses can further enhance their customer experience and SMS campaigns by using some of the MessageMedia platforms more advanced features, like mobile landing pages, and Chatbox to SMS.

Key Points: 
  • Businesses can further enhance their customer experience and SMS campaigns by using some of the MessageMedia platforms more advanced features, like mobile landing pages, and Chatbox to SMS.
  • Our new direct integration with BigCommerce eliminates the complexity of communicating with consumers by offering automation and seamless omnichannel experiences, enabling organizations to retain strong customer relationships as they grow their business."
  • BigCommerce is the most recent addition to a growing list of leading technology partners to have integrated with MessageMedia, joining HubSpot and NetSuite, among others.
  • BigCommerce (Nasdaq: BIGC) is a leading open software-as-a-service (SaaS) ecommerce platform that empowers merchants of all sizes to build, innovate and grow their businesses online.